Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
5000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2012-01-01
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. It will enroll approximately 5000 pre-dialysis chronic kidney disease patients aged between 18 and 74 years in mainland China and follow-up for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at baseline and annually. The principal clinical outcomes of the study consist of renal disease events, cardiovascular events, and death.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease
NCT03246191
Chronic Kidney Disease
UNKNOWN
China Kidney Patient Trials Network
NCT05036850
Kidney Diseases
RECRUITING
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
NCT05476627
Chronic Kidney Diseases
Hypertension
Diabetes Mellitus
+2 more
RECRUITING
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
NCT05188885
Chronic Kidney Disease
RECRUITING
Chinese Observational Prospective Study of Aging Population With Chronic Kidney Disease(C-OPTION)
NCT03246204
Chronic Kidney Disease
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is a multicenter prospective cohort study, aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. The study will establish a baseline cohort of 5000 Chinese pre-dialysis chronic kidney disease patients, who will be followed up until death or dropout or starting renal replacement therapy. The follow-up will be conducted for at least 5 years. Their clinical information and biomaterials will be collected at baseline and then annually during follow-up.
The baseline visit includes the following items: detailed demographics; socioeconomic and health care services information; medical and family history; medication history; and questionnaires concerning quality of life, health behaviors, depressive and anxiety symptoms, cognitive function, and physical activity. Anthropometric measures (height, weight, waist circumference, hip circumference, resting blood pressure, heart rate, grip strength, and 15-feet measured walk) will also be collected. The laboratory parameters of chemistry test, intact parathyroid hormone, 24-hour urine electrolytes, protein creatinine ratio, and albumin creatinine ratio should also be collected for each participant and measured in the central laboratory. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection.
The principal clinical outcomes of the study can be broadly categorized as renal disease events, cardiovascular events, and death. Renal disease events include the incident end stage renal disease or significant loss of renal function.Cardiovascular events include acute myocardial infarction, unstable angina, hospitalization for congestive heart failure, incident serious cardiac arrhythmia, cerebrovascular events, and peripheral vascular diseases. Death is further clarified as cardiac, cerebrovascular, renal, others, or unknown.
The baseline visit includes the following items: detailed demographics; socioeconomic and health care services information; medical and family history; medication history; and questionnaires concerning quality of life, health behaviors, depressive and anxiety symptoms, cognitive function, and physical activity. Anthropometric measures (height, weight, waist circumference, hip circumference, resting blood pressure, heart rate, grip strength, and 15-feet measured walk) will also be collected. The laboratory parameters of chemistry test, intact parathyroid hormone, 24-hour urine electrolytes, protein creatinine ratio, and albumin creatinine ratio should also be collected for each participant and measured in the central laboratory. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection.
The principal clinical outcomes of the study can be broadly categorized as renal disease events, cardiovascular events, and death. Renal disease events include the incident end stage renal disease or significant loss of renal function.Cardiovascular events include acute myocardial infarction, unstable angina, hospitalization for congestive heart failure, incident serious cardiac arrhythmia, cerebrovascular events, and peripheral vascular diseases. Death is further clarified as cardiac, cerebrovascular, renal, others, or unknown.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Renal Insufficiency, Chronic
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Kidney Disease
Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR \<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with "nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment.
Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Intervention Type
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants should meet the following criteria of enrollment according to their etiology of nephrology.
* For glomerular nephrology patients, the estimated glomerular filtration rate (eGFR) should be ≥15 ml/minute per 1.73m(2).
* For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with "nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio (ACR) ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio (PCR).
* For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2)≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment.
* For glomerular nephrology patients, the estimated glomerular filtration rate (eGFR) should be ≥15 ml/minute per 1.73m(2).
* For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with "nephrotic range" proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio (ACR) ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio (PCR).
* For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2)≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment.
Exclusion Criteria
Participants meeting even one of the listed items should be excluded.
* NYHA Class III or IV heart failure.
* Chronic kidney disease caused by systemic inflammatory illness or autoimmune disease, such as lupus erythematosus.
* Treated with immunosuppressive agents in the preceding 6 months to treat renal or immune disease.
* Self-reported or known diagnosis of HIV infection and/or AIDS.
* Isolated hematuria.
* Self-reported or known diagnosis of cirrhosis.
* Pregnant or breast-feeding women.
* Malignancy treated with chemotherapy within last 2 years.
* Renal or other transplantation.
* Hereditary kidney disease.
* Participation in interventional clinical trial.
* NYHA Class III or IV heart failure.
* Chronic kidney disease caused by systemic inflammatory illness or autoimmune disease, such as lupus erythematosus.
* Treated with immunosuppressive agents in the preceding 6 months to treat renal or immune disease.
* Self-reported or known diagnosis of HIV infection and/or AIDS.
* Isolated hematuria.
* Self-reported or known diagnosis of cirrhosis.
* Pregnant or breast-feeding women.
* Malignancy treated with chemotherapy within last 2 years.
* Renal or other transplantation.
* Hereditary kidney disease.
* Participation in interventional clinical trial.
Minimum Eligible Age
18 Years
Maximum Eligible Age
74 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Sponsor Role
collaborator
Dongzhimen Hospital, Beijing
OTHER
Sponsor Role
collaborator
Beijing Hospital
OTHER_GOV
Sponsor Role
collaborator
Beijing Boai Hospital
OTHER
Sponsor Role
collaborator
Peking University Shenzhen Hospital
OTHER
Sponsor Role
collaborator
First Affiliated Hospital of Guangxi Medical University
OTHER
Sponsor Role
collaborator
Guizhou Provincial People's Hospital
OTHER
Sponsor Role
collaborator
First Affiliated Hospital of Chengdu Medical College
OTHER
Sponsor Role
collaborator
Affiliated Hospital of Hebei University
OTHER
Sponsor Role
collaborator
The Second Hospital of Hebei Medical University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Zhengzhou University
OTHER
Sponsor Role
collaborator
the Affiliated Hospital of Hubei Traditional Chinese Medical College
UNKNOWN
Sponsor Role
collaborator
Xiangya Hospital of Central South University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital with Nanjing Medical University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Dalian Medical University
OTHER
Sponsor Role
collaborator
Chifeng Second Hospital
UNKNOWN
Sponsor Role
collaborator
The First Affiliated Hospital of BaoTou Medical College
OTHER
Sponsor Role
collaborator
Qilu Hospital of Shandong University
OTHER
Sponsor Role
collaborator
Shandong Provincial Hospital
OTHER_GOV
Sponsor Role
collaborator
Qianfoshan Hospital
OTHER
Sponsor Role
collaborator
Second Hospital of Shanxi Medical University
OTHER
Sponsor Role
collaborator
Minhang Central Hospital
UNKNOWN
Sponsor Role
collaborator
West China Hospital
OTHER
Sponsor Role
collaborator
Sichuan Provincial People's Hospital
OTHER
Sponsor Role
collaborator
Tianjin Medical University General Hospital
OTHER
Sponsor Role
collaborator
Tianjin Medical University Second Hospital
OTHER
Sponsor Role
collaborator
the First Affiliated Hospital of the Medical College of Shihezi University
UNKNOWN
Sponsor Role
collaborator
First Affiliated Hospital of Xinjiang Medical University
OTHER
Sponsor Role
collaborator
The Second Affiliated Hospital of Kunming Medical University
OTHER
Sponsor Role
collaborator
Yuxi City People's Hospital
UNKNOWN
Sponsor Role
collaborator
Zhejiang University
OTHER
Sponsor Role
collaborator
Xinqiao Hospital of Chongqing
OTHER
Sponsor Role
collaborator
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Sponsor Role
collaborator
First Affiliated Hospital of Chongqing Medical University
OTHER
Sponsor Role
collaborator
The Second Hospital of Anhui Medical University
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Anhui Medical University
OTHER
Sponsor Role
collaborator
General Hospital of Ningxia Medical University
OTHER
Sponsor Role
collaborator
Shengjing Hospital
OTHER
Sponsor Role
collaborator
Peking University First Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Minghui Zhao
Director of Renal Division, Department of Medicine
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minghui Zhao, MD, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Deng X, Gao B, Wang F, Zhao MH, Wang J, Zhang L. Red Blood Cell Distribution Width Is Associated With Adverse Kidney Outcomes in Patients With Chronic Kidney Disease. Front Med (Lausanne). 2022 Jun 9;9:877220. doi: 10.3389/fmed.2022.877220. eCollection 2022.
Reference Type
RESULT
Hui M, Ma J, Yang H, Gao B, Wang F, Wang J, Lv J, Zhang L, Yang L, Zhao M. ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study. J Clin Med. 2023 Feb 14;12(4):1504. doi: 10.3390/jcm12041504.
Reference Type
RESULT
Xue X, Li JX, Wang JW, Lin LM, Cheng H, Deng DF, Xu WC, Zhao Y, Zou XR, Yuan J, Zhang LX, Zhao MH, Wang XQ. Association between alkaline phosphatase/albumin ratio and the prognosis in patients with chronic kidney disease stages 1-4: results from a C-STRIDE prospective cohort study. Front Med (Lausanne). 2023 Sep 20;10:1215318. doi: 10.3389/fmed.2023.1215318. eCollection 2023.
Reference Type
RESULT
Gao B, Zhang L, Wang H, Zhao M. Chinese cohort study of chronic kidney disease: design and methods. Chin Med J (Engl). 2014;127(11):2180-5.
Reference Type
BACKGROUND
Zhou C, Wang F, Wang JW, Zhang LX, Zhao MH. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.
Reference Type
RESULT
Yuan J, Zou XR, Han SP, Cheng H, Wang L, Wang JW, Zhang LX, Zhao MH, Wang XQ; C-STRIDE study group. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017 Jan 14;18(1):23. doi: 10.1186/s12882-017-0441-9.
Reference Type
RESULT
Peng Z, Wang J, Yuan Q, Xiao X, Xu H, Xie Y, Wang W, Huang L, Zhong Y, Ao X, Zhang L, Zhao M, Tao L, Zhou Q; C-STRIDE study group. Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). BMC Nephrol. 2017 Oct 13;18(1):311. doi: 10.1186/s12882-017-0725-0.
Reference Type
RESULT
Yan Z, Wang Y, Li S, Wang J, Zhang L, Tan H, Li S, Yang L, Pei H, Zhang L, Wang Y, Duan J, Jiao S, Zhao M, Fu S; China National Survey of Chronic Kidney Disease Working Group. Hypertension Control in Adults With CKD in China: Baseline Results From the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Am J Hypertens. 2018 Mar 10;31(4):486-494. doi: 10.1093/ajh/hpx222.
Reference Type
RESULT
Zhang JJ, Yang L, Huang JW, Liu YJ, Wang JW, Zhang LX, Zhao MH, Liu ZS. Characteristics and comparison between diabetes mellitus and non-diabetes mellitus among chronic kidney disease patients: A cross-sectional study of the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Oncotarget. 2017 Nov 10;8(63):106324-106332. doi: 10.18632/oncotarget.22368. eCollection 2017 Dec 5.
Reference Type
RESULT
Lv L, Wang F, Wu L, Wang JW, Cui Z, Hayek SS, Wei C, Reiser J, He K, Zhang L, Chen M, Zhao MH. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. Nephrol Dial Transplant. 2020 Mar 1;35(3):465-470. doi: 10.1093/ndt/gfy265.
Reference Type
RESULT
Lv L, Wang J, Gao B, Wu L, Wang F, Cui Z, He K, Zhang L, Chen M, Zhao MH. Serum uromodulin and progression of kidney disease in patients with chronic kidney disease. J Transl Med. 2018 Nov 19;16(1):316. doi: 10.1186/s12967-018-1693-2.
Reference Type
RESULT
Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, Xie Y, Wang W, Huang L, Tang W, Sun D, Zhang L, Wang F, Zhao MH, Tao L, He K, Xu H; C-STRIDE study group. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J Transl Med. 2019 Mar 15;17(1):86. doi: 10.1186/s12967-019-1808-4.
Reference Type
RESULT
Wu L, Li XQ, Chang DY, Zhang H, Li JJ, Wu SL, Zhang LX, Chen M, Zhao MH. Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease. Nephrol Dial Transplant. 2020 Feb 1;35(2):291-297. doi: 10.1093/ndt/gfy314.
Reference Type
RESULT
Liu B, Wang Q, Wang Y, Wang J, Zhang L, Zhao M; C-STRIDE study group. Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE). J Clin Hypertens (Greenwich). 2020 Jan;22(1):57-64. doi: 10.1111/jch.13761. Epub 2019 Dec 9.
Reference Type
RESULT
Pu L, Zou Y, Wu SK, Wang F, Zhang Y, Li GS, Wang JW, Zhang LX, Zhao MH, Wang L; C-STRIDE study group. Prevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J Psychosom Res. 2020 Jan;128:109869. doi: 10.1016/j.jpsychores.2019.109869. Epub 2019 Nov 13.
Reference Type
RESULT
Chen L, Wang J, Huang X, Wang F, Liang W, He Y, Liao Y, Zhang L, Zhao M, Xiong Z; C-STRIDE study group. Association between diabetes mellitus and health-related quality of life among patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Health Qual Life Outcomes. 2020 Aug 3;18(1):266. doi: 10.1186/s12955-020-01519-5.
Reference Type
RESULT
Wang Q, Wang Y, Wang J, Zhang L, Zhao MH; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). White-coat hypertension and incident end-stage renal disease in patients with non-dialysis chronic kidney disease: results from the C-STRIDE Study. J Transl Med. 2020 Jun 15;18(1):238. doi: 10.1186/s12967-020-02413-w.
Reference Type
RESULT
Wang Q, Wang Y, Wang J, Zhang L, Zhao MH; C-STRIDE (Chinese Cohort Study of Chronic Kidney Disease)* dagger. Short-Term Systolic Blood Pressure Variability and Kidney Disease Progression in Patients With Chronic Kidney Disease: Results From C-STRIDE. J Am Heart Assoc. 2020 Jun 16;9(12):e015359. doi: 10.1161/JAHA.120.015359. Epub 2020 Jun 6.
Reference Type
RESULT
Wang Q, Wang Y, Wang J, Zhang L, Zhao MH; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE); Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) Collaborators. Nocturnal Systolic Hypertension and Adverse Prognosis in Patients with CKD. Clin J Am Soc Nephrol. 2021 Mar 8;16(3):356-364. doi: 10.2215/CJN.14420920. Epub 2021 Feb 10.
Reference Type
RESULT
Yuan Q, Xie Y, Peng Z, Wang J, Zhou Q, Xiao X, Wang W, Huang L, Tang W, Li X, Zhang L, Wang F, Zhao MH, Tao L, He K, Wanggou S, Xu H; C-STRIDE study group. Urinary magnesium predicts risk of cardiovascular disease in Chronic Kidney Disease stage 1-4 patients. Clin Nutr. 2021 Apr;40(4):2394-2400. doi: 10.1016/j.clnu.2020.10.036. Epub 2020 Oct 23.
Reference Type
RESULT
Shen Y, Wang J, Yuan J, Yang L, Yu F, Wang X, Zhao MH, Zhang L, Zha Y; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2021 Feb 22;22(1):64. doi: 10.1186/s12882-021-02247-8.
Reference Type
RESULT
Wang J, Liu L, He K, Gao B, Wang F, Zhao M, Zhang L, On Behalf Of The Chinese Cohort Study Of Chronic Kidney Disease C-Stride. UMOD Polymorphisms Associated with Kidney Function, Serum Uromodulin and Risk of Mortality among Patients with Chronic Kidney Disease, Results from the C-STRIDE Study. Genes (Basel). 2021 Oct 23;12(11):1687. doi: 10.3390/genes12111687.
Reference Type
RESULT
Wang J, Lv J, He K, Wang F, Gao B, Zhao MH, Zhang L. Longitudinal Follow-Up and Outcomes for Chinese Patients with Stage 1-4 Chronic Kidney Disease. Kidney Dis (Basel). 2021 Oct 27;8(1):72-81. doi: 10.1159/000519190. eCollection 2022 Jan.
Reference Type
RESULT
Wang J, Lv J, He K, Wang F, Gao B, Zhao MH, Zhang L; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Association of left ventricular hypertrophy and functional impairment with cardiovascular outcomes and mortality among patients with chronic kidney disease, results from the C-STRIDE study. Nephrology (Carlton). 2022 Apr;27(4):327-336. doi: 10.1111/nep.14009. Epub 2021 Dec 15.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011BAI10B01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Chronic Kidney Disease at Northeast Taiwan: Biomarker and Multidisciplinary Care
NCT04300387
UNKNOWN
NA
The Diagnosis and Treatment Pattern of CKD in Patients With Cardiovascular Disease- a National Cross-sectional Study
NCT06143995
UNKNOWN
Chronic Kidney Disease Registry Platform Study
NCT06117852
RECRUITING
The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)
NCT03010696
COMPLETED
Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease
NCT02509013
UNKNOWN
Chinese Chronic Renal Insufficiency Study: Based on Smartphone Platform
NCT04229485
UNKNOWN
A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients
NCT04940819
UNKNOWN
NA
China Collaborative Study on Epidemiology of Acute Kidney Injury
NCT03054142
RECRUITING
Uremic Toxins and Outcomes in Chronic Kidney Disease
NCT03711617
RECRUITING
A Clinical Diagnostic System for Intrinsic Acute Kidney Disease
NCT06606522
COMPLETED
Multi-omics Analysis of Chronic Kidney Disease
NCT05543291
UNKNOWN
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
NCT00304148
ACTIVE_NOT_RECRUITING
Early Screening and Diagnosis of CKD
NCT02841371
RECRUITING
Prognosis of Acute Kidney Injury:China Collaborative Study on AKI（CCS-AKI）Study
NCT03061786
RECRUITING
Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics
NCT06383208
RECRUITING
Etiology, Epidemiology and Prognostics of Acute Kidney Injury (AKI)
NCT00953992
COMPLETED
Rapid Kidney Function Decline in Older Adults
NCT06765811
COMPLETED
Population-based Chronic Kidney Disease Cohort at Northern Taiwan
NCT03004898
UNKNOWN
NA
Chronic Kidney Disease Among Hypertensive Patients in Ha'il, Saudi Arabia
NCT05030480
COMPLETED
A Prospective Cohort Study on Prognostic Factors in Patients With Cardiovascular-kidney-metabolic Syndrome
NCT07327606
RECRUITING
A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）
NCT07098416
NOT_YET_RECRUITING
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
NCT05397392
RECRUITING
Acute Kidney Injury in Patients Hospitalized With COVID-19
NCT04316299
COMPLETED